Frontiers in Immunology · 2024 · 16 citations · 70 references
Life SciencesImmunologyPharmacologyCell SignalingImmunopharmacologySignal TransductionCytokine BiologyCytokine Receptor SignalingCytokine SignalingHistamine ReleaseMast Cell ActivationMast Cell PharmacologyCytokine Production By Mast CellsIge Receptor SignalingJak Inhibitor TherapyJak InhibitorsJak-stat Pathway AntagonismJak-stat Signaling PathwayJanus Kinase Inhibitor TherapyJanus Kinase-stat Signaling Activation
Introduction: The Janus kinase (JAK) family includes four cytoplasmic tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) constitutively bound to several cytokine receptors. JAKs phosphorylate downstream signal transducers and activators of transcription (STAT). JAK-STAT5 pathways play a critical role in basophil and mast cell activation. Previous studies have demonstrated that inhibitors of JAK-STAT pathway blocked the activation of mast cells and basophils. Methods: effects of ruxolitinib, a JAK1/2 inhibitor, on IgE- and IL-3-mediated release of mediators from human basophils, as well as substance P-induced mediator release from skin mast cells (HSMCs). Results: ) from human basophils. Ruxolitinib also inhibited anti-IgE- and IL-3-mediated cytokine (IL-4 and IL-13) release from basophils, as well as the secretion of preformed mediators (histamine, tryptase, and chymase) from substance P-activated HSMCs. Discussion: These results indicate that ruxolitinib, inhibiting the release of several mediators from human basophils and mast cells, is a potential candidate for the treatment of inflammatory disorders.
70
Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors
Evan Parganas, Demin Wang, Dimitrios J. Stravopodis et al. · Cell · 1998 · 1.2K citations · Full text